Odinwell reported improved operating results for 2024, with higher revenue and reduced losses, while advancing its bacteria sensor technology and expanding its patent portfolio. Cash reserves declined, and a clinical pilot study is set for 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.